Taxanes for Breast Cancer: An Evidence-Based Review of Randomized Phase II and Phase III Trials
- 1 April 2000
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 1 (1) , 32-40
- https://doi.org/10.3816/cbc.2000.n.002
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26Journal of Clinical Oncology, 1999
- Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast CancerJournal of Clinical Oncology, 1999
- Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 1999
- Preclinical pharmacokinetics of paclitaxel and docetaxelAnti-Cancer Drugs, 1998
- Systematic Reviews: Synthesis of Best Evidence for Clinical DecisionsAnnals of Internal Medicine, 1997
- 345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)European Journal Of Cancer, 1995
- Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors.Cell Biology International, 1994
- Cytoskeletal agents inhibit motility and adherence of human tumor cellsKidney International, 1993